학술논문

In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2022, 33 7, pS1207-pS1207, 1p. Supplement: 7
Subject
Language
English
ISSN
15698041